257 related articles for article (PubMed ID: 30651135)
21. The pattern of p14ARF expression in primary and metastatic human endometrial carcinomas: correlation with clinicopathological features and TP53 pathway alterations.
Olcha P; Cybulski M; Skomra D; Obrzut B; Ignatov A; Jóźwik M; Schneider-Stock R; Semczuk A
Int J Gynecol Cancer; 2010 Aug; 20(6):993-9. PubMed ID: 20683407
[TBL] [Abstract][Full Text] [Related]
22. Epithelial cell-derived periostin functions as a tumor suppressor in gastric cancer through stabilizing p53 and E-cadherin proteins via the Rb/E2F1/p14ARF/Mdm2 signaling pathway.
Lv H; Liu R; Fu J; Yang Q; Shi J; Chen P; Ji M; Shi B; Hou P
Cell Cycle; 2014; 13(18):2962-74. PubMed ID: 25486483
[TBL] [Abstract][Full Text] [Related]
23. MDM2 sensitizes a human ovarian cancer cell line.
Mi RR; Ni H
Gynecol Oncol; 2003 Aug; 90(2):238-44. PubMed ID: 12893182
[TBL] [Abstract][Full Text] [Related]
24. Runt-related transcription factor RUNX3 is a target of MDM2-mediated ubiquitination.
Chi XZ; Kim J; Lee YH; Lee JW; Lee KS; Wee H; Kim WJ; Park WY; Oh BC; Stein GS; Ito Y; van Wijnen AJ; Bae SC
Cancer Res; 2009 Oct; 69(20):8111-9. PubMed ID: 19808967
[TBL] [Abstract][Full Text] [Related]
25. Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein.
Abedini MR; Muller EJ; Bergeron R; Gray DA; Tsang BK
Oncogene; 2010 Jan; 29(1):11-25. PubMed ID: 19802016
[TBL] [Abstract][Full Text] [Related]
26. Low p14ARF expression in neuroblastoma cells is associated with repressed histone mark status, and enforced expression induces growth arrest and apoptosis.
Dreidax D; Gogolin S; Schroeder C; Muth D; Brueckner LM; Hess EM; Zapatka M; Theißen J; Fischer M; Ehemann V; Schwab M; Savelyeva L; Westermann F
Hum Mol Genet; 2013 May; 22(9):1735-45. PubMed ID: 23343716
[TBL] [Abstract][Full Text] [Related]
27. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.
Mujoo K; Watanabe M; Nakamura J; Khokhar AR; Siddik ZH
J Cancer Res Clin Oncol; 2003 Dec; 129(12):709-18. PubMed ID: 14513366
[TBL] [Abstract][Full Text] [Related]
28. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
[TBL] [Abstract][Full Text] [Related]
29. Pokemon enhances proliferation, cell cycle progression and anti-apoptosis activity of colorectal cancer independently of p14ARF-MDM2-p53 pathway.
Zhao Y; Yao YH; Li L; An WF; Chen HZ; Sun LP; Kang HX; Wang S; Hu XR
Med Oncol; 2014 Dec; 31(12):288. PubMed ID: 25367850
[TBL] [Abstract][Full Text] [Related]
30. Cisplatin causes cell death via TAB1 regulation of p53/MDM2/MDMX circuitry.
Zhu Y; Regunath K; Jacq X; Prives C
Genes Dev; 2013 Aug; 27(16):1739-51. PubMed ID: 23934659
[TBL] [Abstract][Full Text] [Related]
31. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
Fraser M; Bai T; Tsang BK
Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
[TBL] [Abstract][Full Text] [Related]
32. MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.
Walter RF; Mairinger FD; Ting S; Vollbrecht C; Mairinger T; Theegarten D; Christoph DC; Schmid KW; Wohlschlaeger J
Br J Cancer; 2015 Mar; 112(5):883-90. PubMed ID: 25668009
[TBL] [Abstract][Full Text] [Related]
33. The cancer-associated K351N mutation affects the ubiquitination and the translocation to mitochondria of p53 protein.
Muscolini M; Montagni E; Palermo V; Di Agostino S; Gu W; Abdelmoula-Souissi S; Mazzoni C; Blandino G; Tuosto L
J Biol Chem; 2011 Nov; 286(46):39693-702. PubMed ID: 21953469
[TBL] [Abstract][Full Text] [Related]
34. Transforming growth factor β1 (TGF-β1) suppresses growth of B-cell lymphoma cells by p14(ARF)-dependent regulation of mutant p53.
Chen G; Ghosh P; O'Farrell T; Munk R; Rezanka LJ; Sasaki CY; Longo DL
J Biol Chem; 2012 Jun; 287(27):23184-95. PubMed ID: 22621932
[TBL] [Abstract][Full Text] [Related]
35. Dynamics in the p53-Mdm2 ubiquitination pathway.
Brooks CL; Gu W
Cell Cycle; 2004 Jul; 3(7):895-9. PubMed ID: 15254415
[TBL] [Abstract][Full Text] [Related]
36. Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.
Zanjirband M; Edmondson RJ; Lunec J
Oncotarget; 2016 Jun; 7(26):40115-40134. PubMed ID: 27223080
[TBL] [Abstract][Full Text] [Related]
37. Analysis of JNK, Mdm2 and p14(ARF) contribution to the regulation of mutant p53 stability.
Buschmann T; Minamoto T; Wagle N; Fuchs SY; Adler V; Mai M; Ronai Z
J Mol Biol; 2000 Jan; 295(4):1009-21. PubMed ID: 10656807
[TBL] [Abstract][Full Text] [Related]
38. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.
Yan X; Fraser M; Qiu Q; Tsang BK
Gynecol Oncol; 2006 Aug; 102(2):348-55. PubMed ID: 16545436
[TBL] [Abstract][Full Text] [Related]
39. Relationship between p53-associated proteins and estrogen receptor status in ovarian serous neoplasms.
Cho EY; Choi YL; Chae SW; Sohn JH; Ahn GH
Int J Gynecol Cancer; 2006; 16(3):1000-6. PubMed ID: 16803476
[TBL] [Abstract][Full Text] [Related]
40. [p14ARF enhances cisplatin-induced apoptosis in human osteosarcoma cells in p53-independent pathway].
Huang X; Yuan X; Chen Z; Liang S
Zhonghua Yi Xue Za Zhi; 2015 Sep; 95(35):2875-9. PubMed ID: 26815194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
